Skip to the content
Search
Beyond Type 2
Menu
BEYOND TYPE 2
Show sub menu
About
Our Story
Founding Partners
Board of Directors
Leadership Council
The Team
Join Us
Contact
Diabetes
Type 1 Info
Type 2 Info
Prediabetes Info
Forms of Diabetes
Newly Diagnosed
Diabetes Management
Pregnancy and Diabetes
Resources
GetInsulin.org
Insulin for T2D
Diabetes Management
Understanding T2D
Exercise
Food
Heart Health
Mental Health
Continuous Glucose Monitoring (CGM)
Veterans with Diabetes
Beyond Type 2 Advocacy
Stories
Diabetes News
Type 2 Stories
Community
Beyond Type 2 App
Marathon Team
En Español
Search
Invisible:
news
A New Medication Targeting Three Hormones
Retatrutide, a new medication, is showing promising results for the treatment of several diseases including type 2 diabetes.
A Year in Review: Advancements in Diabetes Tech + Research
This session reviewed the advances and discoveries in research and technology for people living with diabetes over the past year.
Senseonics + UnitedHealthcare Expanding CGM Access
Senseonics announced that UnitedHealthCare will now cover their Eversense E3 implantable CGM, starting July 1, 2023.
Omnipod GO Receives FDA Approval for Adults with Type 2 Diabetes
This FDA approval marks the first-of-its-kind of a basal-only tubeless insulin pod for adults with type 2 diabetes.
Eli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes
Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.
Diabetes news
Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Affordable
Mark Cuban's Cost Plus Drugs Company just announced that they offer Janssen's Invokana, Invokamet and Invokamet XR for type 2 diabetes.
California Partners with Civica Rx to Make More Affordable Insulin
California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.
Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35
Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024.
Novo Nordisk to Slash Insulin Prices by over 65%
Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.
Posts navigation
←
Newer
Posts
1
…
3
4
5
…
20
Older
Posts
→